Non-small cell lung cancer and elevated eosinophil count: A case report and literature review

Venkatesan, Rohit; Salam, Amir; Alawin, Issam; Willis, Maurice

doi:10.1016/j.ctrc.2015.05.002

Cited by 5 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The significant difference in the EO# between lung cancer samples ( P <.001) and negative samples is indicated in this study as well. There is a common view that paraneoplastic processes and distant metastases (to the bone marrow) will increase EO# to some extent [50]. Alkaline phosphatase (ALP) is reported to be associated with cancer metastasis in the literature [51], and it was also a critical index for identifying lung cancer and negative samples in our analysis.…”

Section: Discussionmentioning

confidence: 97%

A Machine Learning Method for Identifying Lung Cancer Based on Routine Blood Indices: Qualitative Feasibility Study

Wu¹,

Zan²,

Gao³

et al. 2019

JMIR Med Inform

View full text Add to dashboard Cite

Background Liquid biopsies based on blood samples have been widely accepted as a diagnostic and monitoring tool for cancers, but extremely high sensitivity is frequently needed due to the very low levels of the specially selected DNA, RNA, or protein biomarkers that are released into blood. However, routine blood indices tests are frequently ordered by physicians, as they are easy to perform and are cost effective. In addition, machine learning is broadly accepted for its ability to decipher complicated connections between multiple sets of test data and diseases. Objective The aim of this study is to discover the potential association between lung cancer and routine blood indices and thereby help clinicians and patients to identify lung cancer based on these routine tests. Methods The machine learning method known as Random Forest was adopted to build an identification model between routine blood indices and lung cancer that would determine if they were potentially linked. Ten-fold cross-validation and further tests were utilized to evaluate the reliability of the identification model. Results In total, 277 patients with 49 types of routine blood indices were included in this study, including 183 patients with lung cancer and 94 patients without lung cancer. Throughout the course of the study, there was correlation found between the combination of 19 types of routine blood indices and lung cancer. Lung cancer patients could be identified from other patients, especially those with tuberculosis (which usually has similar clinical symptoms to lung cancer), with a sensitivity, specificity and total accuracy of 96.3%, 94.97% and 95.7% for the cross-validation results, respectively. This identification method is called the routine blood indices model for lung cancer, and it promises to be of help as a tool for both clinicians and patients for the identification of lung cancer based on routine blood indices. Conclusions Lung cancer can be identified based on the combination of 19 types of routine blood indices, which implies that artificial intelligence can find the connections between a disease and the fundamental indices of blood, which could reduce the necessity of costly, elaborate blood test techniques for this purpose. It may also be possible that the combination of multiple indices obtained from routine blood tests may be connected to other diseases as well.

show abstract

Section: Discussionmentioning

confidence: 97%

A Machine Learning Method for Identifying Lung Cancer Based on Routine Blood Indices: Qualitative Feasibility Study

Wu¹,

Zan²,

Gao³

et al. 2019

JMIR Med Inform

View full text Add to dashboard Cite

show abstract

“…[2] Several studies suggest that local production of cytokines (GM-CSF, IL-3, and IL-5) by tumour cells is the most likely mechanism, particularly IL-5, which is considered to be the most important eosinophilopoetin. [3][4][5] These cytokines are involved in eosinophil development and maturation, with predominantly IL-5 mobilising eosinophils from bone marrow into the blood.…”

Section: Discussionmentioning

confidence: 99%

“…However, case reports suggest that this is not always feasible, as these patients usually have extensive metastases and poor outcomes. [3][4][5] …”

Section: Discussionmentioning

confidence: 99%

Hypereosinophilia as a paraneoplastic phenomenon in non-small cell lung carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…It has been associated with a better prognosis in certain types of cancers like colorectal and esophageal squamous cell carcinoma, but with a poor outcome in patients with Hodgkin's lymphoma. 1 Concerning lung cancer, 3,4 and specifically nonsmall cell lung cancer (NSCLC), with the most common sub-type being lung adenocarcinoma, 2 hyper-eosinophilia has been consistently associated with extensive metastasis, poor response to therapy and overall a worse prognosis, particularly when a paraneoplastic process is functioning as the cause. 3 Pembrolizumab, one of the immune checkpoint inhibitors (ICI) used in the treatment of lung cancer, have recently revolutionized treatment in oncology, showing evidence of improved survival compared to conventional platinum-based chemotherapy in lung malignancy.…”

Section: Introductionmentioning

confidence: 99%

“…1 Concerning lung cancer, 3,4 and specifically nonsmall cell lung cancer (NSCLC), with the most common sub-type being lung adenocarcinoma, 2 hyper-eosinophilia has been consistently associated with extensive metastasis, poor response to therapy and overall a worse prognosis, particularly when a paraneoplastic process is functioning as the cause. 3 Pembrolizumab, one of the immune checkpoint inhibitors (ICI) used in the treatment of lung cancer, have recently revolutionized treatment in oncology, showing evidence of improved survival compared to conventional platinum-based chemotherapy in lung malignancy. 5 Early hyper-eosinophilia appearing following NSCLC treatment with ICI has been previously reported with contradictory outcomes.…”

Section: Introductionmentioning

confidence: 99%

Lung Adenocarcinoma with Paraneoplastic Hyper-Eosinophilia Not Responding To Pembrolizumab

Wehbe

Kozah

Koubaissi

2021

Clin Med Insights Circ Respir Pulm Med

View full text Add to dashboard Cite

Background: Paraneoplastic hyper-eosinophilia associated with metastatic lung adenocarcinoma is a rare finding and has been associated with a poor prognosis when present. Early hyper-eosinophilia appearing following non-small cell lung cancer (NSCLC) treatment with immune checkpoint inhibitors (ICI) has been previously reported with contradictory outcomes. Case summary: We present the case of an elderly man with newly diagnosed metastatic lung adenocarcinoma and baseline hyper-eosinophilia, treated with pembrolizumab, and showing evidence of significant and rapid disease progression suggestive of hyper-progressive disease, worsening baseline hyper-eosinophilia, and a fatal outcome within 1 month of therapy initiation. Conclusion: Pre-treatment hyper-eosinophilia could represent a predictive factor of an unfavorable response to ICI treatment in cases of NSCLC. Additional similar cases are needed to draw a more conclusive relationship.

show abstract

Non-small cell lung cancer and elevated eosinophil count: A case report and literature review

Cited by 5 publications

References 6 publications

A Machine Learning Method for Identifying Lung Cancer Based on Routine Blood Indices: Qualitative Feasibility Study

A Machine Learning Method for Identifying Lung Cancer Based on Routine Blood Indices: Qualitative Feasibility Study

Hypereosinophilia as a paraneoplastic phenomenon in non-small cell lung carcinoma

Lung Adenocarcinoma with Paraneoplastic Hyper-Eosinophilia Not Responding To Pembrolizumab

Contact Info

Product

Resources

About